Novartis: Ovarian cancer drug disappoints in trial

May 27, 2010

(AP) -- Swiss drug maker Novartis AG said Thursday it won't ask regulators for permission to market a new ovarian cancer drug after a late-stage trial proved disappointing.

The drug, patupilone, failed to show improvements over existing drugs in 829 patients with advanced .

"Novartis does not plan to proceed with regulatory filings based on these data," the Basel-based company said.

Patupilone also is being tested for treatment of certain types of colorectal, lung and .

Shares in Novartis closed 1.6 percent higher at 51.85 Swiss francs ($45.01) in line with a general lift on the Zurich exchange.

Explore further: EU approves Avastin for lung cancer

0 shares

Related Stories

Second-generation CML drugs show promise as frontline therapy

December 8, 2008

Two drugs approved as fallback therapy for chronic myelogenous leukemia (CML) appear to outperform historical benchmarks of the frontline medication when used as a first treatment in separate clinical trials, researchers ...

Roche to take over Genentech for $47 billion

March 12, 2009

(AP) -- Swiss pharmaceutical giant Roche said Thursday it has agreed to buy California-based Genentech for $46.8 billion in a takeover described as the largest in Swiss corporate history.

Novartis says on track to deliver US vaccine order

October 29, 2009

(AP) -- Swiss drugmaker Novartis AG said Thursday it is on track to meet its U.S. government order for swine flu vaccine, seeking to calm fears in recent weeks that shipments and vaccination programs may be delayed.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Caliban
1 / 5 (1) May 27, 2010
What a drag for Novartis!!! Not only do they lose billions in profits, but they have that much less capital to live up to the double-digit quarterly dividend that their shareholders demand.
This kind of failure is inevitable for as long as BigPharma relies on the "Profit Foremost" model of drug development. Currently, if a drug candidate shows any promise(as in, can we rush this to market?), then it will be fast-tracked in preference to another that may show greater effectiveness, but may take longer to develop, refine, and trial.
If it's all about cashflow and marketing, then the quality of the product is going to suffer, and so I laugh every time I see them step on their own dick like this. Just imagine if you or I indulged in this sort of planning. It would be just as wise to use a casino visit to determine your budget.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.